MedTrace Logo

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

NCT01666704 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-21

No results posted yet for this study

Summary

The purpose of the study is to assess the effect of BMS-823778 on reducing atherosclerotic plaque inflammation

Conditions

Interventions

DRUG

BMS-823778

Capsules, Oral, 2mg, Once daily, 1 year

DRUG

BMS-823778

Capsules, Oral, 15mg, Once daily, 1 year

DRUG

Placebo matching with BMS-823778

Capsules, Oral, 0mg, Once daily, 1 year

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-10-31
Completion
2016-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01666704 on ClinicalTrials.gov